Bactericidal activity, absence of serum effect, and time-kill kinetics of ceftazidime-avibactam against β-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa

Avibactam, a non-β-lactam β-lactamase inhibitor with activity against extended-spectrum β-lactamases (ESBLs), KPC, AmpC, and some OXA enzymes, extends the antibacterial activity of ceftazidime against most ceftazidime-resistant organisms producing these enzymes. In this study, the bactericidal activ...

Full description

Saved in:
Bibliographic Details
Published in:Antimicrobial agents and chemotherapy 2014-09, Vol.58 (9), p.5297-5305
Main Authors: Keepers, Tiffany R, Gomez, Marcela, Celeri, Chris, Nichols, Wright W, Krause, Kevin M
Format: Article
Language:English
Subjects:
Anti-Bacterial Agents
Anti-Bacterial Agents - administration & dosage
Anti-Bacterial Agents - pharmacology
Azabicyclo Compounds
Azabicyclo Compounds - pharmacology
Bacteria
beta-Lactam Resistance - drug effects
Ceftazidime
Ceftazidime - pharmacology
Dose-Response Relationship, Drug
Drug Combinations
Enterobacteriaceae
Enterobacteriaceae - drug effects
Experimental Therapeutics
Humans
Kinetics
Microbial Sensitivity Tests
Pseudomonas aeruginosa
Pseudomonas aeruginosa - drug effects
Serum Albumin - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Avibactam, a non-β-lactam β-lactamase inhibitor with activity against extended-spectrum β-lactamases (ESBLs), KPC, AmpC, and some OXA enzymes, extends the antibacterial activity of ceftazidime against most ceftazidime-resistant organisms producing these enzymes. In this study, the bactericidal activity of ceftazidime-avibactam against 18 Pseudomonas aeruginosa isolates and 15 Enterobacteriaceae isolates, including wild-type isolates and ESBL, KPC, and/or AmpC producers, was evaluated. Ceftazidime-avibactam MICs (0.016 to 32 μg/ml) were lower than those for ceftazidime alone (0.06 to ≥256 μg/ml) against all isolates except for 2 P. aeruginosa isolates (1 blaVIM-positive isolate and 1 blaOXA-23-positive isolate). The minimum bactericidal concentration/MIC ratios of ceftazidime-avibactam were ≤4 for all isolates, indicating bactericidal activity. Human serum and human serum albumin had a minimal effect on ceftazidime-avibactam MICs. Ceftazidime-avibactam time-kill kinetics were evaluated at low MIC multiples and showed time-dependent reductions in the number of CFU/ml from 0 to 6 h for all strains tested. A ≥3-log10 decrease in the number of CFU/ml was observed at 6 h for all Enterobacteriaceae, and a 2-log10 reduction in the number of CFU/ml was observed at 6 h for 3 of the 6 P. aeruginosa isolates. Regrowth was noted at 24 h for some of the isolates tested in time-kill assays. These data demonstrate the potent bactericidal activity of ceftazidime-avibactam and support the continued clinical development of ceftazidime-avibactam as a new treatment option for infections caused by Enterobacteriaceae and P. aeruginosa, including isolates resistant to ceftazidime by mechanisms dependent on avibactam-sensitive β-lactamases.
ISSN:0066-4804
1098-6596
DOI:10.1128/AAC.02894-14